Papilloma virus truncated L1 protein and fusion protein constructs

• US 20050249745A1
• Filed: 07/13/2005
• Published: 11/10/2005
• Est. Priority Date: 02/20/1998
• Status: Active Grant

• Current Assignee: Medigene AG
• Original Assignee: Medigene AG
• Inventors: Hallek, Michael, Burger, Alexander
• Granted Patent: US 7,494,658 B2
• Time in Patent Office: Days
• US Class Current: 424/186.100
• CPC Class Codes: A61K 2039/5258 Virus-like particles
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/20023 Virus like particles [VLP]
• CPC Class Codes: C12N 2710/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Vaccine formulations comprising, viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.

Claims

1. A fusion protein comprising:

an amino acid sequence from a first papilloma-virus specific (PVS) protein; and

an amino acid sequence from a second PVS protein,

wherein said fusion protein comprises only PVS protein amino acid sequences.

2. A fusion protein in accordance with claim 1, comprising amino acid sequences from more than two PVS proteins.

3. A fusion protein in accordance with claim 1, wherein at least one of the amino acid sequences from a PVS protein comprises at least one deletion from the naturally-occurring PVS protein sequence.

4. A fusion protein in accordance with claim 1, wherein said first PVS protein is a L protein or E protein.

5. A fusion protein in accordance with claim 4, wherein the L protein is L1.

6. A fusion protein in accordance with claim 1, wherein the E protein is E7 protein.

7. A fusion protein in accordance with claim 1, wherein the first PVS protein is a L protein, and the second PVS protein is an E protein.

8. A fusion protein in accordance with claim 7, wherein said L protein is L1 and said E protein is E7.

9. A fusion protein in accordance with claim 8, wherein the PVS proteins are human PVS proteins.

10. A fusion protein in accordance with claim 9, wherein said amino acid sequence from said L1 protein does not contain the 34 amino acid sequence of the carboxy terminus.

11. A nucleic acid sequence encoding the fusion protein of claim 1.

12. A nucleic acid sequence in accordance with claim 11 that is a DNA.

13. A therapeutic composition comprising the fusion protein of claim 1.

14. A prophylactic vaccine formulation comprising the fusion protein of claim 1.

15. A method of making the fusion protein of claim 1, comprising recombinant expression of a nucleic acid sequence encoding said fusion protein, and substantially isolating said fusion protein.

16. A therapeutic method of treating an animal having a papilloma virus infection, comprising administration of a pharmaceutical composition comprising the fusion protein of claim 1 in an amount and for a period of time sufficient to reduce the level of papilloma virus infection.

17. A therapeutic method in accordance with claim 16, wherein the animal is a human and the PVS proteins are human PVS proteins.

18. A prophylactic method of inhibiting a papilloma virus infection in an animal, comprising administration of a pharmaceutical composition comprising the fusion protein of claim 1 in an amount and for a period of time sufficient to effectively inhibit papilloma virus infection.

19. A therapeutic method in accordance with claim 18, wherein the animal is a human and the PVS proteins are human PVS proteins.